Melanoma

In Melanoma, Older Adults Could Benefit More From Treatment With PD-1 Inhibitors

In Melanoma, Older Adults Could Benefit More From Treatment With PD-1 Inhibitors

By

Patient age should play a role in drug development strategies for melanoma, researchers of a new study say.

Long-Term Data Show Nivolumab May Provide Sustained Benefit Compared With Ipilimumab

Long-Term Data Show Nivolumab May Provide Sustained Benefit Compared With Ipilimumab

By

Preliminary findings from CheckMate 238 show treatment with nivolumab significantly prolonged recurrence-free survival compared with ipilimumab in patients with resected stage III/IV melanoma after a minimum 18-month follow-up.

Complete Lymph Node Dissection May Not Improve Outcomes in Melanoma

Complete Lymph Node Dissection May Not Improve Outcomes in Melanoma

By

When compared with watchful waiting, CLND did not improve survival outcomes among patients with malignant melanoma who have positive SLNB.

Latest AJCC Edition Staging System May Not Be As Effective in Differentiating Survival in Melanoma

Latest AJCC Edition Staging System May Not Be As Effective in Differentiating Survival in Melanoma

By

Study authors conducted a study comparing the prognostic and discriminatory ability for survival with the 7th and 8th Editions.

Encorafenib Plus Binimetinib for Metastatic Melanoma

Encorafenib Plus Binimetinib for Metastatic Melanoma

Victor Sandor, MD, discusses the treatment combination at the ASCO 2018 meeting in Chicago.

Marital Status Predicts Melanoma Stage at Diagnosis—But Why?

Marital Status Predicts Melanoma Stage at Diagnosis—But Why?

By

Married people are more likely than unmarried, divorced, or widowed patients to be diagnosed with skin cancer at early, more readily-treatable stages of disease.

Melanoma: FDA Approves Adjuvant Dabrafenib With Trametinib

Melanoma: FDA Approves Adjuvant Dabrafenib With Trametinib

By

The FDA based its approval on the results of the phase 3 COMBI-AD study.

The Benefits of Adjuvant Immunotherapy in Melanoma

The Benefits of Adjuvant Immunotherapy in Melanoma

By

KEYNOTE-054 may show whether some patients with resected disease can forego adjuvant therapy.

SLNBs Feasible After Wide Local Excisions in Melanoma of the Head and Neck

SLNBs Feasible After Wide Local Excisions in Melanoma of the Head and Neck

By

Sentinel nodes were accurately identified in all 30 patients who underwent WLE.

Late-Onset Toxicity Possible With Immunotherapy

Late-Onset Toxicity Possible With Immunotherapy

By

Postapproval studies are needed to further characterize the risk and long-term safety of immune checkpoint inhibition.

Adjuvant Pembrolizumab Reduces Risk of Recurrence in Stage III Melanoma

Adjuvant Pembrolizumab Reduces Risk of Recurrence in Stage III Melanoma

By

Improvement in RFS was seen regardless of PD-L1 status.

Nivolumab With/Without Ipilimumab Active in Melanoma Brain Metastases

Nivolumab With/Without Ipilimumab Active in Melanoma Brain Metastases

By

Grade 3 to 4 adverse events were observed in 54% (19), 16% (4), and 13% (2) of patients in Cohorts A, B, and C, respectively.

USPSTF: Behavioral interventions do not reduce sunburn or skin cancer outcomes

This systematic review analyzed the current evidence on the benefits and harms of behavioral counseling for skin cancer prevention and found that these interventions can increase sun protection behavior.

Encorafenib, Binimetinib May Be Effective in <i>BRAF</i>-Mutant Melanoma

Encorafenib, Binimetinib May Be Effective in BRAF-Mutant Melanoma

By

One death possibly related to treatment was, however, noted in the combination group.

Selumetinib Plus Dacarbazine Does Not Improve Uveal Melanoma Outcomes

Selumetinib Plus Dacarbazine Does Not Improve Uveal Melanoma Outcomes

By

Researchers randomly assigned 129 patients with previously untreated metastatic uveal melanoma to receive dacarbazine plus selumetinib or placebo.

Interest in Oncolytic Viruses Continues To Grow

Interest in Oncolytic Viruses Continues To Grow

By

A variety of viruses are being researched in cancers including melanoma, brain tumors, breast cancers, and others.

Combining Chemotherapy With Immunotherapy To Improve Response Rates

Combining Chemotherapy With Immunotherapy To Improve Response Rates

By

The combinatorial approach is not, furthermore, limited to chemotherapy.

Obesity Associated With Improved Melanoma Outcomes

Obesity Associated With Improved Melanoma Outcomes

By

Some observational studies suggest that overweight BMI may have a protective effect during cancer treatment.

Immunotherapy for Metastatic Melanoma — In the Clinic

Immunotherapy for Metastatic Melanoma — In the Clinic

By

The management of toxicities and re-initiation of these medications should be made on a case by case basis.

Melanoma Treatment Regimens

Melanoma Treatment Regimens

View treatment regimens for melanoma, including guidance on options and dosing for a number of drugs including ipilimumab and dacarbazine.

Can Vismodegib Induce Melanoma in Patients Treated for Basal Cell Carcinoma?

Can Vismodegib Induce Melanoma in Patients Treated for Basal Cell Carcinoma?

By

Two cases raise the question of whether abnormal activation of the hedgehog signaling pathway can lead to a protective effect on melanomas.

Encorafenib/Binimetinib Combination Shows Promise for Advanced Melanoma

Encorafenib/Binimetinib Combination Shows Promise for Advanced Melanoma

By

The combination may be an attractive option for some, but further research is needed to target the therapy effectively to particular patients.

Pembrolizumab May Cure Metastatic Melanoma in A Subset of Patients

Pembrolizumab May Cure Metastatic Melanoma in A Subset of Patients

By

Baseline tumor size and PD-L1 status were independently associated with the likelihood of a complete response.

FDA Grants Priority Review to Dabrafenib and Trametinib Combination for Resected Melanoma

FDA Grants Priority Review to Dabrafenib and Trametinib Combination for Resected Melanoma

By

The drug combination was studied in patients with BRAFV600E/K mutations in the phase 3 COMBI-AD study, the results of which led to the FDA's Priority Review designation.

The Challenges of Immunotherapy Re-challenge in Metastatic Melanoma

The Challenges of Immunotherapy Re-challenge in Metastatic Melanoma

By

It is not always clear whether patients who discontinue anti-PD-1 and -CTLA-4 therapy should re-initiate treatment after adverse events are resolved.

Melatonin Analogues May Have Antitumor Properties in Melanoma and Breast Cancer

Melatonin Analogues May Have Antitumor Properties in Melanoma and Breast Cancer

By

Previous studies have demonstrated that melatonin and its analogues, in addition to their ability to regulate circadian rhythms, may exhibit cytotoxic activity via various cellular mechanisms.

Study Reveals Widespread Non-compliance With Indoor Tanning Regulations

Study Reveals Widespread Non-compliance With Indoor Tanning Regulations

By

Four hundred and twenty-seven tanning salons were contacted; 32.7% of contacted salons were non-compliant with their respective state's regulations.

FDA Grants Breakthrough Therapy Designation to Adjuvant Dabrafenib Plus Trametinib for Melanoma

FDA Grants Breakthrough Therapy Designation to Adjuvant Dabrafenib Plus Trametinib for Melanoma

By

Dabrafenib plus trametinib is the first adjuvant therapy indicated specifically for melanoma with the BRAFV600 mutation.

PAK Inhibition Could Abrogate MAPK Inhibitor Resistance in BRAF-mutant Melanoma

PAK Inhibition Could Abrogate MAPK Inhibitor Resistance in BRAF-mutant Melanoma

By

Researchers found that cells resistant to both BRAF inhibition and combination inhibition were sensitive to PAK inhibition, and further that PAK inhibition slowed cell-cycle progression.

Long-term Survival From Ipilimumab/Nivolumab Combination in Metastatic Melanoma

Long-term Survival From Ipilimumab/Nivolumab Combination in Metastatic Melanoma

By

Mario Sznol, MD, of the Yale University School of Medicine in New Haven, Connecticut, discusses melanoma clinical trial results just published in the Journal of Clinical Oncology.

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs